Clinical trial • Phase IV • Endocrinology
Estradiol for Turner syndrome
Phase IV trial of Estradiol for Turner syndrome.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Turner syndrome
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 18-09-2024
- First CTIS Authorization Date
- 08-10-2024
Trial design
Oral estradiol (Estrofem, film-coated tablets) versus transdermal estradiol (Divigel 1 mg gel); dose and schedule not specified in the available record-controlled Phase IV trial in Denmark.
- Comparator
- Oral estradiol (Estrofem, film-coated tablets) versus transdermal estradiol (Divigel 1 mg gel); dose and schedule not specified in the available record
- Target Sample Size
- 100
Eligibility
Recruits 100 No vulnerable population selected (isVulnerablePopulationSelected: false). Consent/assent handling for vulnerable populations is not described..
- Pregnancy Exclusion
- Pregnancy
- Vulnerable Population
- No vulnerable population selected (isVulnerablePopulationSelected: false). Consent/assent handling for vulnerable populations is not described.
Inclusion criteria
- {"criterion_text":"- Diagnosis of Turner syndrome regardless of karyotype (Turner syndrome)\n- Age 18-50 years (Turner syndrome and healthy controls)\n- Already receiving estrogen treatment (Turner syndrome)\n- Female (healthy controls)\n- Previously healthy (healthy controls)\n- Not receiving any medication (healthy controls)\n- Not using any form of contraceptive pills (healthy controls)\n- No mental or psychiatric disorders (healthy controls)"}
Exclusion criteria
- {"criterion_text":"- Active systemic chronic diseases\n- Known or suspected breast cancer\n- Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n- Untreated endometrial hyperplasia\n- Current or previous venous thromboembolism\n- Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n- Known hypersensitivity to the medications used\n- Pregnancy\n- Menopause (healthy controls only)"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Body composition: measured by bio impedance","definition_or_measurement_approach":"measured by bio impedance"}
- {"endpoint_text":"- Blood test values: changes in the blood test values from baseline within the areas of metabolism, endocrinology, cardiovascular function, and coagulation","definition_or_measurement_approach":"changes in blood test values from baseline within areas of metabolism, endocrinology, cardiovascular function, and coagulation"}
- {"endpoint_text":"- Cardiovascular status: 24-hour ambulatory blood pressure monitoring and arterial stiffness (measured by SphygmoCor)","definition_or_measurement_approach":"24-hour ambulatory blood pressure monitoring and arterial stiffness measured by SphygmoCor"}
- {"endpoint_text":"- Muscle quality: MR scan of both quadriceps measuring muscle cross-sectional area (CSA) and fat content of the muscle. Maximal isometric muscle strength of both quadriceps (functional muscle tests). Muscle quality = maximum quadriceps strength measured in nM/muscle CSA.","definition_or_measurement_approach":"MR scan of quadriceps measuring muscle CSA and fat content; maximal isometric quadriceps strength (functional tests); muscle quality defined as maximum quadriceps strength in nM divided by muscle CSA"}
- {"endpoint_text":"- Quadriceps strength test: maximal isometric muscle strength of both quadriceps measured simultaneously","definition_or_measurement_approach":"maximal isometric muscle strength of both quadriceps measured simultaneously"}
- {"endpoint_text":"- Isometric hand strength test: maximal hand strength measured in kilograms","definition_or_measurement_approach":"maximal hand strength measured in kilograms"}
- {"endpoint_text":"- Fitness: maximal oxygen uptake measured by a VO2max test","definition_or_measurement_approach":"maximal oxygen uptake measured by a VO2max test"}
- {"endpoint_text":"- Bones: bone mineral density as measured by a DEXA scan","definition_or_measurement_approach":"bone mineral density measured by DEXA scan"}
- {"endpoint_text":"- Jumping heigth: maximal jumping heigth measured in centimeters","definition_or_measurement_approach":"maximal jumping height measured in centimeters"}
Secondary endpoints
- {"endpoint_text":"- Self-reported health-related quality of life and functioning (SF-36)","definition_or_measurement_approach":"Self-reported health-related quality of life and functioning measured by SF-36"}
- {"endpoint_text":"- Self-reported quality of life (WHOQoL-Bref)","definition_or_measurement_approach":"Self-reported quality of life measured by WHOQoL-Bref"}
- {"endpoint_text":"- Subjective assesment of the medication after 6 months of oral and six months of transdermal treatment","definition_or_measurement_approach":"Subjective assessment of the medication after 6 months of oral and 6 months of transdermal treatment"}
Recruitment
- Planned Sample Size
- 100
- Recruitment Window Months
- 60
- Consent Approach
- Subject information and informed consent forms are listed (L1_SIS patients, L1_SIS controls, L1_ICF patients, L1_ICF controls, L1_ICF_biobank documents). Informed consent is required from adult participants; no assent or proxy consent procedures for minors/vulnerable groups are described.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 100
Denmark
- Earliest CTIS Part Ii Submission Date
- 30-09-2024
- Latest Decision Or Authorization Date
- 08-10-2024
- Processing Time Days
- 8
- Number Of Sites
- 1
- Number Of Participants
- 100
Sites
- Site Name
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital
- Department Name
- Endocrinology and Internal Medicine
- Contact Person Name
- Camilla Mains Balle
- Contact Person Email
- camibl@clin.au.dk
Sponsor
Primary sponsor
- Full Name
- Region Midtjylland
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Aarhus Universitet","duties_or_roles":"sponsorDuties code 1","organisation_type":"Educational Institution"}
Investigational products
- Investigational Product Name
- Estrofem, filmovertrukne tabletter
- Active Substance
- Estradiol
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Authorised (marketing authorisation number 06697, Denmark)
- Dose Levels
- maxDailyDoseAmount: 10 mg; maxTotalDoseAmount: 2100 mg; maxTreatmentPeriod: 7 (timeUnitCode 3)
- Maximum Dose
- 10 mg (max daily)
- Investigational Product Name
- Divigel 1 mg gel
- Active Substance
- Estradiol
- Modality
- Small molecule
- Routes Of Administration
- TRANSDERMAL USE
- Route
- TRANSDERMAL USE
- Authorisation Status
- Authorised (marketing authorisation number 13296, Sweden)
- Dose Levels
- maxDailyDoseAmount: 10 mg; maxTotalDoseAmount: 2100 mg; maxTreatmentPeriod: 7 (timeUnitCode 3)
- Maximum Dose
- 10 mg (max daily)
Related trials
Other published trials that may interest you.